Understand the source comparison
Peptides for Back Pain: Research vs Clinical Use Comparison
BPC-157 Upregulates growth hormone receptors in fibroblasts; accelerates collagen synthesis in ligaments and annular tears 250–500 mcg/day subcutaneous, near injury site, 4–8 weeks Rodent models show 72% increase in tendon tensile strength; human data limited
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Upregulates growth hormone receptors in fibroblasts; accelerates collagen synthesis in ligaments and annular tears
- 250–500 mcg/day subcutaneous, near injury site, 4–8 weeks
- Rodent models show 72% increase in tendon tensile strength; human data limited to case reports
- Subcutaneous (localized) or intramuscular (paraspinal)
- Most evidence-supported for connective tissue repair; mechanism directly targets structural pathology in discs and ligaments
- TB-500 (Thymosin Beta-4 fragment)
- Inhibits NF-kB pathway to reduce cytokine-driven inflammation; promotes angiogenesis via VEGF upregulation
- 2–2.5 mg twice weekly, 4–8 weeks; front-load 5 mg x2 in week 1
- Phase 2 trials for wound healing show accelerated closure; musculoskeletal applications extrapolated from preclinical data
- Subcutaneous (systemic) or intramuscular (localized)
- Best for inflammation-dominant pain where structural imaging is unremarkable but cytokine cascade perpetuates symptoms
- Thymalin
- Immune modulation via thymic peptide signaling; systemic anti-inflammatory effects
- 5–10 mg daily, 10–20 days; primarily studied for immune reconstitution
- Russian literature shows immune parameter normalization; musculoskeletal evidence weak
- Subcutaneous or intramuscular
- Limited direct evidence for back pain; may support systemic inflammation reduction in autoimmune-linked cases
- KPV (alpha-MSH tripeptide)
- Potent anti-inflammatory via melanocortin receptor activation; inhibits NF-kB and MAPK pathways
- 500 mcg–1 mg daily, subcutaneous or oral, 4–6 weeks
- Preclinical models show cytokine suppression; human trials ongoing for inflammatory bowel disease
- Subcutaneous, intramuscular, or oral (gut inflammation focus)
- Mechanistically promising for systemic inflammation but lacks specific musculoskeletal trial data; emerging compound